Cargando…

Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis

Detalles Bibliográficos
Autores principales:	He, Rong, Devine, Daniel J., Tu, Zheng Jin, Mai, Ming, Chen, Dong, Nguyen, Phuong L., Oliveira, Jennifer L., Hoyer, James D., Reichard, Kaaren K., Ollila, Paul L., Al-Kali, Aref, Tefferi, Ayalew, Begna, Kebede H., Patnaik, Mrinal M., Alkhateeb, Hassan, Viswanatha, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608401/ https://www.ncbi.nlm.nih.gov/pubmed/31591496 http://dx.doi.org/10.1038/s41379-019-0378-6

Ejemplares similares

Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis
por: He, Rong, et al.
Publicado: (2019)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients
por: He, Rong, et al.
Publicado: (2022)

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations
por: Venable, Elise R, et al.
Publicado: (2021)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
por: Grob, Tim, et al.
Publicado: (2023)

Flt3 Ligand Regulates Dendritic Cell Development from Flt3(+) Lymphoid and Myeloid-committed Progenitors to Flt3(+) Dendritic Cells In Vivo
por: Karsunky, Holger, et al.
Publicado: (2003)

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3
por: Nagai, Kozo, et al.
Publicado: (2018)

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
por: Eisfelder, Bartholomew J., et al.
Publicado: (2021)

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r
por: Boudry, Augustin, et al.
Publicado: (2022)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells
por: Chen, Fangli, et al.
Publicado: (2016)

Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience
por: Gangat, Naseema, et al.
Publicado: (2022)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors
por: Lim, Sung Hee, et al.
Publicado: (2016)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Pim-1 Kinase Phosphorylates and Stabilizes 130 kDa FLT3 and Promotes Aberrant STAT5 Signaling in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
por: Natarajan, Karthika, et al.
Publicado: (2013)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience
por: Katamesh, Bahga, et al.
Publicado: (2022)

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
por: Cueto, Francisco J., et al.
Publicado: (2021)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
por: Maiorova, Varvara, et al.
Publicado: (2023)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
por: Hellesøy, Monica, et al.
Publicado: (2021)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

Altered compensatory cytokine signaling underlies the discrepancy between Flt3(–/–) and Flt3l(–/–) mice
por: Durai, Vivek, et al.
Publicado: (2018)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21(Cdkn1a) and Pbx1 in Hematopoietic Cells
por: Abe, Mariko, et al.
Publicado: (2016)

Mast cell sarcoma: 2 Mayo Clinic cases
por: Singh, Amritpal, et al.
Publicado: (2022)

Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k0r4vmismqljo1pd65if0ocqqc